Company intelligence / Profile preview

A3P Biomedical

Stockholm, Sweden

Ownership: Private
Development stage: Commercial

Overview

Stockholm3 has been clinically validated in studies involving over 75,000–90,000 men. It detects 41–100% more aggressive prostate cancers than standard PSA testing while reducing unnecessary biopsies by up to 50% and over-detection of indolent cancers by up to 52%. The test has been published in high-impact journals such as The Lancet Oncology and Journal of Clinical Oncology[1][2][3].

Therapeutic areas: Oncology
Modalities: Blood-based diagnostic test (combining protein biomarkers, genetic biomarkers, and clinical data analyzed by a proprietary algorithm)
Industry: Molecular Diagnostics

Drug pipeline

1 asset

Stockholm3

Commercial

Indications: Prostate cancer

Partnerships

BioAgilytix (for US market introduction of Stockholm3 as an LDT)

Beyond the preview

Go deeper on A3P Biomedical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on A3P Biomedical.

Explore the full profile